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Abstract
Introduction The purpose of this case is to present
the use of pattern electroretinogram (PERG) in the
early diagnosis of normal-tension preperimetric glau-
coma in 56 years old woman.
Methods and Results At baseline the results were as
follows: distance-corrected visual acuity in the right
eye (RE) and left eye (LE) 1.0 and 0.7, respectively
(Snellen table), normal anterior segments in both eyes,
normal fundus in the RE and abnormal cup to disc ratio
(0.6) in the LE. Intraocular pressure (IOP) was within
normal limits in both eyes: RE-14 mmHg, LE-18
mmHg (Goldmann tonometer). Results of standard
automated perimetry (SAP), short wavelength auto-
mated perimetry (SWAP) and nerve fiber analyzer
(GDx) were normal in both eyes. PERG result was
normal in the RE but in the LE reduced amplitudes of
P50 and N95 waves were observed. After topical
treatment (Xalacom to the LE), a reduction of IOP to 13
mmHg was achieved and was accompanied by ampli-
tudes increase of PERG waves. After discontinuation
of the therapy, IOP increased to 18 mmHg and P50 and
N95 amplitudes decreased to the values before treat-
ment, suggesting the influence of IOP lowering therapy
on electrical function of retinal ganglion cells. After 4
years from the baseline, static perimetry results were
still normal, but abnormalities in retinal nerve fiber
layer thickness were detected in GDx.
Conclusions PERG was a useful test not only for the
early diagnosis of normal-tension preperimetric glau-





Normal-tension glaucoma is defined as a primary
open-angle glaucoma (POAG), where all signs of the
disease are present, except from the elevated intraoc-
ular pressure (IOP). Normal-tension POAG is diag-
nosed on the basis of the optic nerve head damage
typical for glaucoma, open anterior chamber angle in
gonioscopy, glaucomatous visual field (VF) defects,
and normal IOP, which is not higher than 21 mmHg
without treatment [1]. Unfortunately, there are no
characteristic abnormalities of either VF or optic disc
that can be diagnostic for the normal-tension glau-
coma [2]. Although the pathomechanism of normal-
tension glaucoma is still unknown, there are some
features that may occur more often with this disease:
female sex, migraine headache, Raynauld phenome-
non, ischemic vascular diseases, autoimmune dis-
eases, and coexistence of macro- and microvascular
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abnormalities or coagulopathies [2, 3]. The diagnosis
of glaucoma becomes more complicated when neither
VF, nor nerve fiber layer shows any pathological
changes. The individual-based decision to start ther-
apy or to wait and observe without treatment may
depend on further investigations and should be
supported by additional data, which will allow to
measure the function of retinal ganglion cells (RGCs)
that are damaged or impaired in glaucoma. An
example of such an examination is a commonly used
and well-known pattern electroretinogram (PERG),
performed according to the International Society for
Clinical Electrophysiology of Vision (ISCEV) [4].
Transient PERG was recorded with the RetiPort
(Roland Consult Instr.) system. Protocol of the PERG
test was implemented in the original software of the
system. Patient’s pupils were not dilated, monocular
stimulation was used, refraction correction was
applied with respect to the eye-screen distance
0.5 m, and interruptions of the test were introduced
when frequent blinking or fixation loose was observed
(patient was monitored with a TV camera).
Parameters of the pattern stimulation were as
follows: 2100 CRT monitor with a frame rate equal to
75 fps was used; black and white reversing checker-
board (30 FOV) was presented to the patient, with a
check size equal to 120; luminance for white elements:
120 cd/m2, contrast: 97 %; temporal frequency was
equal to 4.6 rps (2.3 Hz); and central fixation was used.
Electrodes
Thread DTL electrode was used as active, and gold
disc was placed at the ipsilateral outer canthus as
reference, with ground (gold disc) electrode placed on
the forehead (Fpz).
Parameters of the recording system were as
follows: amplifiers sensitivity: 20 lV/div, filters:
1–100 Hz. Notch filters: off. Artifact reject threshold:
95 % (for the amplifiers range ± 100 lV). Sweep
time: 250 ms (time base: 25 ms/div). Averaging: 200
sweeps. Two consecutive waveforms were recorded,
off-line averaged, and then analyzed.
Results analysis
According to the standard, amplitude as well as time
parameters of the obtained waveforms were analyzed;
manual correction was applied to the automatic
cursors placement. Values of all parameters were
compared with the own laboratory normal values.
In this study, we describe a case, where PERG
strongly suggested a recognition of normal-tension
preperimetric glaucoma 4 years before it was finally
diagnosed, according to the actual criteria: a glauco-
matous appearance of the optic disc head, open
chamber angle, and thinning of retinal nerve fiber
layer (RNFL) thickness measured by GDx or optical
coherence tomography (OCT), with normal VF,
confirmed by at least two following standard auto-
mated perimetry (SAP) examinations [5].
Case
A 56-year-old healthy white female was examined by
an ophthalmologist, because her mother suffered from
glaucoma in both eyes and she wanted to check
herself. In a routine ophthalmological examination at
baseline, patient’s distance-corrected visual acuity
(DCVA) was 1.0 in the right eye (RE) and 0.7 in the
left eye (LE) (Snellen table). IOP was 14 mmHg and
18 mmHg in the right and left eyes, respectively
(Goldmann tonometer). The anterior segments were
normal in both eyes including open anterior chamber
in gonioscopy. Stereoscopic fundus examination
result was normal in the RE and the only abnormality
in the LE was an increased cup-to-disc ratio (c/d ratio
0.6) (Fig. 1), what was confirmed by Heidelberg
retinal tomography (HRT). Pachymetry results were
normal and equal to 517 and 521 lm in the RE and LE,
respectively. In both eyes, SAP, short wavelength
automated perimetry (SWAP) results, and RNFL
thickness measured by GDx were as well within
normal limits (Fig. 2). Additionally, PERG test was
performed and the results were as follows: RE—
normal amplitude (A) of P50 (6.8 lV) and A N95
(9.6 lV) waves, LE—reduced amplitudes of P50
(2.4 lV) and N95 (4.1 lV) waves. Implicit time of
the RE and LE was normal and equal to 53.6 and
50.9 ms, respectively (Fig. 3). In our laboratory, the
established normal values (mean ± 2SD) for this
patient’s age are as follows: A P50: 3.2–11.3 lV; IT
P50: 46.5–59.2 ms; A N95: 4.8–15.7 lV. According
to the well-known guidelines, the coefficient of
variation (CV) of amplitude for the transient PERG
is 9 ± 1 % [6] and we assumed, according to the study
presented by other authors [7], that an increase or
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123
decrease in PERG amplitude is diagnosed when it
exceeds 20 %.
In this case, in the LE, normal-tension preperimet-
ric glaucoma was suspected, because of the repeatable
abnormal PERG results, increased c/d ratio in the LE,
and higher IOP in the LE in comparison with the RE.
We decided the instillation one drop of Xalatan
(Latanoprost) to the LE once a day, but because after
1 month, IOP reduction was less than 25 % (from 18
to 16 mmHg, 11 % decrease) and the treatment was
changed to Xalacom (Latanoprost ? Timolol) in the
same regiment. After 3 months from the beginning of
the therapy, the IOP in the LE decreased up to
13 mmHg (28 % fall from the baseline) and the
patient was referred to the electrophysiological labo-
ratory to repeat the PERG. The values of the ampli-
tudes in the LE much improved [A P50 from 2.4 to
3.8 lV (58 % growth, CV = 32 %), A N95 from 4.1
to 6.3 lV (54 % growth, CV = 30 %)] and suggested
the improvement of RGCs function (Fig. 4). After the
above-mentioned treatment, the amplitudes achieved
values near lower limits of normal. Implicit time
values did not show any changes. For checking that
IOP-lowering therapy is the cause of RGCs’ function
Fig. 1 Fundus photographs of the right (a) and left (b) eyes.
Increased cup-to-disc ratio (0, 6) in the left eye was detected
Fig. 2 Gdx results in both
eyes within normal limits
Fig. 3 Right eye (left side):
PERG amplitudes of P50
and N95 waves within
normal limits. Left eye
(right side): lower PERG
amplitudes of P50 and N95
waves
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improvement, we decided to stop Xalacom instillation
for 1 month. After this time period, IOP in the LE
increased to the initial value (18 mmHg), and in the
control, PERG A of P50 and N95 waves again
decreased to the following values: A P50: from 3.8
to 1.5 lV (60 % decrease, CV = 61 %), A N95: from
6.3 to 3.4 lV (46 % decrease, CV = 42 %) (Fig. 5).
Implicit time values did not show any changes. The
decision to include Xalacom to the LE as a permanent
therapy was made.
At the follow-up, 8 months later, the IOP in the LE
was equal to 12 mmHg and to check again RGSc’
function, the patient was referred to the electrophys-
iological laboratory to repeat the PERG. In this
examination, both amplitudes did not differ much
with the values at baseline: A P50 (3 % fall,
CV = 2 %) and A N95 (8 % growth, CV = 6 %).
IT values again did not show any changes.
Once a year, in our patient, the following examin-
ations were performed: SAP, SWAP, Gdx, and PERG.
No considerable changes with the previous results
were detected in above-mentioned tests. After 4 years
from the initial examination, static perimetry tests
were repeated. Both SAP and SWAP results were still
normal in the LE. Additionally, to find out whether the
reduced function of RGCs in the LE corresponds with
the abnormalities in RNFL, Gdx was performed
(Fig. 6). Its results revealed abnormal thickness of
Fig. 4 Left eye: increase in
PERG amplitudes after
instillation of Xalacom
(right side), in comparison
with the score before
treatment (left side)
Fig. 5 Left eye: decrease in
PERG amplitudes after
1-month discontinuation of
Xalacom therapy (left side
treated eye, right side
without treatment)
Fig. 6 Left eye: gdx result after 4 years of follow-up: abnormal thickness of RNFL in the lower quadrant and a pathological nerve fiber
index (NFI) = 43
56 Doc Ophthalmol (2014) 128:53–58
123
RNFL in the lower quadrant and a pathological nerve
fiber index (NFI), which was 43 in the LE. At this
point, the normal-tension preperimetric glaucoma was
decisively diagnosed in the LE, because it was in an
agreement with a current definition of this disease.
Discussion
Normal-tension preperimetric glaucoma may be dif-
ficult to diagnose for the ophthalmologist and is
complicated for the patient, who may have difficulties
with understanding that he really suffers from glau-
coma, even though his IOP and VFs are normal. To
diagnose, very often, additional glaucomatous tests
are needed. In our case report, apart from commonly
used tests, PERG was performed. It is known from the
literature that PERG may be an early glaucoma
indicator in either OHT patients, or glaucoma suspects
[8–10]. The results of these surveys showed that
PERG helped to identify glaucoma-suspected patients,
whose perimetry results were normal [9] or who had
OHT and were at a high risk to develop glaucoma in
the future [8, 10, 11]. Additionally, it is documented
that PERG can measure the influence of IOP-lowering
treatment on RGCs function in early glaucoma [12]
and glaucoma suspects [13]. These promising results
were the reason, why in our difficult diagnostic
patient, PERG was registered.
In the presented case, initial results of commonly
used tests like Gdx, SAP, and SWAP were normal
in both eyes. The reasons to start pharmacological
IOP-lowering therapy in the LE were as follows:
family glaucomatous history, asymmetry of IOP
between eyes (in the LE 4 mmHg higher than in the
RE), increased c/d ratio (0.6) in the LE confirmed
by HRT, lack of other systemic and eye diseases
that could destroy an electrical function of RGCs,
and finally, reduced PERG amplitudes of P50 and
N95 waves at baseline, only in the LE. Nowadays,
European Glaucoma Society (EGS) recommends
25 % decrease in IOP from baseline [1] to reduce
the risk of progression by 50 % in cases of early
glaucoma patients. Because after instillation of
Xalatan (Latanoprost), IOP was reduced less than
25 % and Xalacom (Bimatoprost ? Timolol) was
fprescribed. This drug is known to meet the
criteria of EGS connected with an appropriate
lowering IOP [14].
After 3 months of Xalacom therapy, IOP decreased
(28 %) what was accompanied with PERG amplitudes
increase. It suggested that at the time of the treatment’s
initiation, glaucoma was at its early stage, and
therefore, some RGCs were just dysfunctional and so
their partial function’s improvement after IOP-lower-
ing therapy was possible and detected by PERG. Such
an improvement was described also by Ventura et al.
[[15], [13]]. In these studies, instillation of IOP-
lowering therapy in early glaucoma patients was also a
cause of RGCs function improvement. In the pre-
sented case, increased IOP and associated decreased
PERG amplitudes after 1-month discontinuation of
Xalacom confirmed that IOP-lowering therapy was the
cause of RGCs’ recovery.
This study’s results also show that even properly
treated normal-tension glaucoma, which according to
the collaborative normal-tension glaucoma study
group means decreased IOP of 30 % from the baseline
[16], does not have to stop the impairment of
following RGCs. In the case of this patient, even
though the IOP reduction near 30 % was obtained,
after 8 months of treatment, the PERG amplitudes
were not higher, but did not differ much with the initial
values, what was another indicator of progressive
destruction of RGCs, typical for glaucoma. The fact
that glaucoma is a progressive disease, despite the
drug therapy, is well known, especially in the normal-
tension glaucoma, caused by multifocal components,
where IOP-lowering treatment cannot stop the pro-
gression either [16]. The consequences of progressive
loss of RGCs were the characteristic features observed
in Gdx after 4 years from the baseline, manifested by
nerve fiber loss. Such a sequence of events is
consistent with the well-known information in the
literature that PERG can detect RGCs dysfunction that
occurs before cell death [18] and the changes of RNFL
thickness are found in structural tests like Gdx before
VF loss detected by SAP [19].
In conclusion, PERG was a useful test for the early
diagnosis of normal-tension preperimetric glaucoma
before the changes in other studies were observed. Its
results enabled not only to start antiglaucomatous
treatment 4 years before the diagnosis according to the
actual criteria, but also to evaluate the effectiveness of
the therapy. What is the most important, early
inclusion of the treatment reducing IOP, with a high
probability, slowed down a progression of glaucoma-
tous optic neuropathy in this case.
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